Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, John Rose, Timothy R. Vollmer et al.|The Lancet Neurology|2010Cited by 300